Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
McKesson
McKinsey
Baxter
Express Scripts
AstraZeneca

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR AKYNZEO

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

All Clinical Trials for AKYNZEO

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03008213 Combination of Netupitant and Palonosetron (Akynzeo®) in the Treatment of Refractory CINV Terminated University of California, San Diego Phase 2 2017-01-01 Prevention and control of Chemotherapy-Induced Nausea and Vomiting (CINV) are most important in treatment of cancer patients. CINV is one of the most distressing severe side effects of cancer treatment and can have a significant impact on a patient's quality of life. The chemotherapy agents that cause the worst degree of nausea and vomiting are categorized into two groups: moderately emetogenic chemotherapy (MEC) and highly emetogenic chemotherapy (HEC). Nausea and vomiting that occurs within the first day of the administration of chemotherapy agents is considered acute CINV, while nausea and vomiting following 24 hours of the administration of chemotherapy agents is considered delayed CINV. Refractory CINV occurs when patients develop CINV during subsequent cycles of chemotherapy when drugs preventing vomiting and nausea (antiemetic prophylaxis) has not been successful in controlling CINV in earlier cycles. The purpose of this study is to assess the efficacy of Akynzeo in the treatment of refractory CINV
NCT03040726 Netupitant and Palonosetron (AKYNZEO) for Chronic Nausea and Vomiting in Cancer Patients Not yet recruiting Helsinn Healthcare SA Phase 2/Phase 3 2017-06-01 The goal of this clinical research study is to learn if netupitant/palonosetron can help to decrease chronic nausea and vomiting in patients with cancer. The safety of the study drug will also be studied. Some participants will receive the study drug and some will receive a placebo. A placebo is not a drug. It looks like the study drug but is not designed to treat any disease or illness. It is designed to be compared with a study drug to learn if the study drug has any real effect.
NCT03040726 Netupitant and Palonosetron (AKYNZEO) for Chronic Nausea and Vomiting in Cancer Patients Not yet recruiting M.D. Anderson Cancer Center Phase 2/Phase 3 2017-06-01 The goal of this clinical research study is to learn if netupitant/palonosetron can help to decrease chronic nausea and vomiting in patients with cancer. The safety of the study drug will also be studied. Some participants will receive the study drug and some will receive a placebo. A placebo is not a drug. It looks like the study drug but is not designed to treat any disease or illness. It is designed to be compared with a study drug to learn if the study drug has any real effect.
NCT03403712 A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cance Recruiting George Clinical Pty Ltd Phase 3 2018-03-16 Multicenter, randomized, double-blind, double-dummy, parallel group, stratified study assessing the safety and describing the efficacy of a single dose of intraveneous (IV) fosnetupitant/palonosetron (260 mg/0.25 mg) infusion [test] versus oral netupitant/palonosetron (300 mg/0.5 mg) combination [control]; each administered with oral dexamethasone prior to initial and repeated cycles of AC chemotherapy in female breast cancer patients.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for AKYNZEO

Condition Name

Condition Name for AKYNZEO
Intervention Trials
Chemotherapy-induced Nausea and Vomiting 2
In Situ Neoplasm 1
Chemotherapy Induced Nausea Vomiting 1
Cervical Cancer 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for AKYNZEO
Intervention Trials
Vomiting 5
Nausea 3
Neoplasms 1
Uterine Cervical Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for AKYNZEO

Trials by Country

Trials by Country for AKYNZEO
Location Trials
United States 17
Georgia 1
France 1
Denmark 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for AKYNZEO
Location Trials
Mississippi 1
Arkansas 1
New Jersey 1
New Mexico 1
Ohio 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for AKYNZEO

Clinical Trial Phase

Clinical Trial Phase for AKYNZEO
Clinical Trial Phase Trials
Phase 4 1
Phase 3 1
Phase 2/Phase 3 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for AKYNZEO
Clinical Trial Phase Trials
Recruiting 3
Terminated 1
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for AKYNZEO

Sponsor Name

Sponsor Name for AKYNZEO
Sponsor Trials
Helsinn Healthcare SA 3
M.D. Anderson Cancer Center 1
University of California, San Diego 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for AKYNZEO
Sponsor Trials
Industry 5
Other 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
McKesson
Moodys
McKinsey
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.